Akums Drugs & Pharmaceuticals Ltd Q1 FY26 – India’s CDMO Giant with a Zambia-sized Ambition and Europe Contract Buzz
1. At a Glance
Akums Drugs is India’s answer to “pharma outsourcing at scale,” holding over 30% share of the Indian CDMO market. The company supplies everyone from Cipla to Dabur, runs 12 factories churning out 49 billion units a year, and just raised ₹1,856 Cr in IPO funds. Yet, the stock is down 44% in one year—because growth hasn’t kept pace with the hype. The big question: will its Zambia JV and €200M Europe contract make Akums the Sun Pharma of CDMOs, or just another mid-cap pharma story with fancy press releases?
2. Introduction
Imagine being the ghostwriter of Indian pharma. You don’t write the novel (discover the molecule), you don’t market the book (brand building), but you do all the grunt work of typing, printing, and binding. That’s Akums for you—the invisible hand behind 26 of India’s top 30 pharma companies.
Founded in 2004, Akums has built its empire by quietly doing contract manufacturing across dosage forms—tablets, syrups, injections, eye drops, even gummies. In short: if it can be swallowed, injected, or applied, Akums probably makes it.
The IPO in FY25 brought in nearly ₹1,856 Cr—of which ₹680 Cr fresh issue was earmarked for debt repayment, working capital, and acquisitions. Debt is already down to just ₹88 Cr, making Akums almost debt-free.
But here’s the twist: revenue growth has slowed to low single digits, while profits grew largely due to cost control. Investors expecting “India’s Lonza” are watching margins like TRP ratings.
So, is Akums the backroom giant finally stepping onto the main stage, or will it remain a supporting actor in the pharma blockbuster?
3. Business Model – WTF Do They Even Do?
Akums operates as a Contract Development and Manufacturing Organization (CDMO)—basically the “factory-for-hire” of pharma.
CDMO Business (78% revenue): Largest in India. Makes formulations for 26 of the top 30 pharma cos.
Branded & Generics (17%): Through its subsidiaries Akumentis & Unosource.
12 manufacturing units with 49.2 billion unit capacity.
4 R&D units, 2 DSIR-approved.
Over 4,100 commercialized formulations across 60 dosage forms.
Clientele: Cipla, Dr. Reddy’s, Dabur, Alkem, Alembic—basically a “who’s who” of Indian pharma. Repeat orders from 38 of top 50 clients (FY24).
Global footprint: Present in 65 countries, but India still contributes 93.5% of revenue. Africa (Zambia JV) and Europe (contract wins) may finally diversify.
Detective lens: Akums is the back-end partner nobody sees, but everybody needs. The trouble? Margins are thin, dependence on Indian clients is high, and growth depends on capturing global scale.
